Undertreatment with anti-osteoporotic drugs after hospitalization for fracture.
about
Odanacatib for the treatment of postmenopausal osteoporosis.Treatment of postmenopausal osteoporosis with odanacatib.Management of osteoporotic vertebral fracturesPost-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study.Orthopedic surgeon's awareness can improve osteoporosis treatment following hip fracture: a prospective cohort study.Fracture prevention service to bridge the osteoporosis care gapPharmacotherapy of osteoporosis in men.PTH 1-84: bone rebuilding as a target for the therapy of severe osteoporosis.Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage.The NYU Osteoporosis Model of Care Experience.Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle.Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinionsThe Adequacy of Diagnosis and Treatment for Osteoporosis in Patients with Proximal Humeral Fractures.Association of gastrointestinal events and osteoporosis treatment initiation in newly diagnosed osteoporotic Israeli women.Osteoporosis management among residents living in long-term care.Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.Monitoring pharmacological therapy for osteoporosis.Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis.Overcoming problems with adherence to osteoporosis medication.Effects of medication reviews performed by a physician on treatment with fracture-preventing and fall-risk-increasing drugs in older adults with hip fracture-a randomized controlled study.Insights from the Global Longitudinal Study of Osteoporosis in Women (GLOW).Emerging drugs for osteoporosis.A sample of Canadian orthopedic surgeons expressed willingness to participate in osteoporosis management for fragility fracture patients.High prevalence of missed opportunities for secondary fracture prevention in a regional general hospital setting in Singapore.Prescription of anti-osteoporosis medications after hospitalization for hip fracture: a multicentre Italian survey.Use of anti-osteoporotic drugs in central Norway after a forearm fracture.Bridging the osteoporosis quality chasm.Cost-effectiveness of the Concord Minimal Trauma Fracture Liaison service, a prospective, controlled fracture prevention study.Hip fracture and other predictors of anti-osteoporosis drug use in Norway.User-only design to assess drug effectiveness in clinical practice: application to bisphosphonates and secondary prevention of fractures.Factors Affecting Bone Mineral Density Measurement after Fracture in South Korea.Equal treatment: no evidence of gender inequity in osteoporosis management in a coordinator-based fragility fracture screening program.Emerging anabolic agents in the treatment of osteoporosis.Testing and treatment for osteoporosis following hip fracture in an integrated U.S. healthcare delivery system.The role of risk communication in the care of osteoporosis.Minodronate for the treatment of osteoporosis.Profile of French community-dwelling older adults supplemented with vitamin D: Findings and lessonsOsteoporosis in men
P2860
Q30683504-116DA4D8-E28D-4F6F-8F48-F5AF3A19A7EAQ30740996-94BE9D56-5307-4931-97C2-19A1AFDBE556Q34041859-4481471E-4752-4381-9EC5-567CF3314346Q34459547-BD0B853C-4D91-44FA-BF9D-4B9FB75D8741Q34587301-696FC332-D63C-4A78-B9D2-8DBE4D46FE96Q35511637-5C1EF010-0603-41F4-A2B8-3E04B93F14F7Q35799111-715990C2-663B-43FD-9A7C-088EB30298A9Q36040673-8CCE377C-4725-4375-B8FB-944DD8AB2D90Q36084571-243772AD-9FF6-4D49-8BB5-434C37921B4AQ36265141-9AB91FBF-B0BB-482B-A940-ABACBCCBE484Q36285804-C620A73E-B227-45A4-ADAB-7743456DE885Q36997750-A7BD01C5-E474-44ED-AC7E-223B9EBF931FQ37058784-15D49884-B73D-4408-8DC7-108DC94B95BDQ37180613-F515B11D-266A-43F4-A09A-270EE2E1D126Q37295877-5E0DF507-97C9-4445-A4CD-72A772185F74Q37401851-0FDCFB61-22DC-4638-A393-F9A15B462E39Q37412956-D94EE4BC-581F-45C0-871F-5EC53EB67FBEQ37565638-E14367DA-034C-4630-80F5-02806776DB0BQ37689559-17869178-D710-4B38-9EDA-637A4CDB4D22Q37813135-2A8AA7BB-56BA-426E-A324-BC0219E4406CQ37820680-D6BD377E-F2B5-45F9-ABA8-56F2461C37CDQ38136708-EDC5B585-7C3C-43C0-AC89-E2E7C14E3635Q38206066-0B178B64-74A2-4011-AD00-9F3BC551E90AQ38226342-F76A1FC5-F35E-429D-BD6F-29AF70CC8BC9Q38522118-145415DE-B3B8-44D6-BEA1-7383BA5DAA46Q38705784-ABE19A06-6A5B-49DA-BA6F-CF81EE3FC3C1Q39109115-CCBC2F60-F352-47B4-9803-7E9D7639E754Q40580195-CCED24D9-BB1E-4B59-9677-33BCC9B812FDQ44198055-C8DB9207-D8E7-4426-80C2-BCABD7EF18CBQ44227480-4CFFDEC9-80D6-4B6A-8D55-B135D2E6AB37Q44820522-C14E335E-3E28-431A-8E49-CE280D217E70Q44985602-8A08B567-A47D-48C9-8E61-AD78C3E57CCDQ47189134-77C2AC1D-656B-4733-9D0D-1EF36D3A6FF6Q48005475-BA2A7250-8726-45CA-8200-46FDFACEE55BQ48012226-A3216C79-E10F-442F-81AC-62E6ABC44251Q48923386-1E342CF8-7FBC-47CB-8CD5-B32139ACEFFEQ51577374-D055B4BA-2F24-47D8-ACEA-406CA9EE02BCQ55077666-E3F9AE5B-779A-4153-B52B-1D6526BCA54BQ56088923-F4B025FF-5877-4BC3-8408-047A69B50936Q56109562-88FD4527-66CC-451B-9C55-7AB2EBC48831
P2860
Undertreatment with anti-osteoporotic drugs after hospitalization for fracture.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Undertreatment with anti-osteoporotic drugs after hospitalization for fracture.
@en
type
label
Undertreatment with anti-osteoporotic drugs after hospitalization for fracture.
@en
prefLabel
Undertreatment with anti-osteoporotic drugs after hospitalization for fracture.
@en
P2093
P1476
Undertreatment with anti-osteoporotic drugs after hospitalization for fracture.
@en
P2093
Martien J M Panneman
Ron M C Herings
Shuvayu S Sen
P2888
P304
P356
10.1007/S00198-003-1544-7
P407
P577
2003-11-13T00:00:00Z
P5875
P6179
1029733134